91 related articles for article (PubMed ID: 31741708)
1. The anti-cancer effects of phenformin in thyroid cancer cell lines and in normal thyrocytes.
Coperchini F; Croce L; Denegri M; Awwad O; Ngnitejeu ST; Magri F; Chiovato L; Rotondi M
Oncotarget; 2019 Nov; 10(60):6432-6443. PubMed ID: 31741708
[TBL] [Abstract][Full Text] [Related]
2. The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors.
Coperchini F; Croce L; Denegri M; Awwad O; Ngnitejeu ST; Muzza M; Capelli V; Latrofa F; Persani L; Chiovato L; Rotondi M
Sci Rep; 2019 Mar; 9(1):4390. PubMed ID: 30867499
[TBL] [Abstract][Full Text] [Related]
3. The AMPK-activator AICAR in thyroid cancer: effects on CXCL8 secretion and on CXCL8-induced neoplastic cell migration.
Awwad O; Coperchini F; Pignatti P; Denegri M; Massara S; Croce L; Di Buduo CA; Abbonante V; Balduini A; Chiovato L; Rotondi M
J Endocrinol Invest; 2018 Nov; 41(11):1275-1282. PubMed ID: 29546654
[TBL] [Abstract][Full Text] [Related]
4. Canagliflozin reduces thyroid cancer cells migration in vitro by inhibiting CXCL8 and CCL2: An additional anti-tumor effect of the drug.
Coperchini F; Greco A; Croce L; Pignatti P; Muzza M; Petrosino E; Teliti M; Magri F; Rotondi M
Biomed Pharmacother; 2024 Jan; 170():115974. PubMed ID: 38056240
[TBL] [Abstract][Full Text] [Related]
5. PFOA, PFHxA and C6O4 differently modulate the expression of CXCL8 in normal thyroid cells and in thyroid cancer cell lines.
Coperchini F; De Marco G; Croce L; Denegri M; Greco A; Magri F; Tonacchera M; Imbriani M; Rotondi M; Chiovato L
Environ Sci Pollut Res Int; 2023 May; 30(23):63522-63534. PubMed ID: 37052835
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D Reduces Thyroid Cancer Cells Migration Independently From the Modulation of CCL2 and CXCL8 Chemokines Secretion.
Coperchini F; Greco A; Croce L; Petrosino E; Grillini B; Magri F; Chiovato L; Rotondi M
Front Endocrinol (Lausanne); 2022; 13():876397. PubMed ID: 35498406
[TBL] [Abstract][Full Text] [Related]
7. Normal human thyroid cells, BCPAP, and TPC-1 thyroid tumor cell lines display different profile in both basal and TNF-α-induced CXCL8 secretion.
Coperchini F; Pignatti P; Leporati P; Carbone A; Croce L; Magri F; Chiovato L; Rotondi M
Endocrine; 2016 Oct; 54(1):123-128. PubMed ID: 26450713
[TBL] [Abstract][Full Text] [Related]
8. Metformin reverts the secretion of CXCL8 induced by TNF-α in primary cultures of human thyroid cells: an additional indirect anti-tumor effect of the drug.
Rotondi M; Coperchini F; Pignatti P; Magri F; Chiovato L
J Clin Endocrinol Metab; 2015 Mar; 100(3):E427-32. PubMed ID: 25590211
[TBL] [Abstract][Full Text] [Related]
9. Effect of Interferon-γ on the Basal and the TNFα-Stimulated Secretion of CXCL8 in Thyroid Cancer Cell Lines Bearing Either the RET/PTC Rearrangement Or the BRAF V600e Mutation.
Rotondi M; Coperchini F; Awwad O; Pignatti P; Di Buduo CA; Abbonante V; Magri F; Balduini A; Chiovato L
Mediators Inflamm; 2016; 2016():8512417. PubMed ID: 27555670
[TBL] [Abstract][Full Text] [Related]
10. TNF-α increases the membrane expression of the chemokine receptor CCR6 in thyroid tumor cells, but not in normal thyrocytes: potential role in the metastatic spread of thyroid cancer.
Coperchini F; Pignatti P; Carbone A; Bongianino R; Di Buduo CA; Leporati P; Croce L; Magri F; Balduini A; Chiovato L; Rotondi M
Tumour Biol; 2016 Apr; 37(4):5569-75. PubMed ID: 26577851
[TBL] [Abstract][Full Text] [Related]
11. Phenformin has anti-tumorigenic effects in human ovarian cancer cells and in an orthotopic mouse model of serous ovarian cancer.
Jackson AL; Sun W; Kilgore J; Guo H; Fang Z; Yin Y; Jones HM; Gilliam TP; Zhou C; Bae-Jump VL
Oncotarget; 2017 Nov; 8(59):100113-100127. PubMed ID: 29245964
[TBL] [Abstract][Full Text] [Related]
12. Interferon-γ and tumor necrosis factor-α sustain secretion of specific CXC chemokines in human thyrocytes: a first step toward a differentiation between autoimmune and tumor-related inflammation?
Rotondi M; Coperchini F; Pignatti P; Sideri R; Groppelli G; Leporati P; La Manna L; Magri F; Mariotti S; Chiovato L
J Clin Endocrinol Metab; 2013 Jan; 98(1):308-13. PubMed ID: 23118425
[TBL] [Abstract][Full Text] [Related]
13. Role of Chemokines in Thyroid Cancer Microenvironment: Is CXCL8 the Main Player?
Rotondi M; Coperchini F; Latrofa F; Chiovato L
Front Endocrinol (Lausanne); 2018; 9():314. PubMed ID: 29977225
[TBL] [Abstract][Full Text] [Related]
14. Type I and type II interferons inhibit both basal and tumor necrosis factor-α-induced CXCL8 secretion in primary cultures of human thyrocytes.
Rotondi M; Coperchini F; Sideri R; Groppelli G; de Martinis L; Villani L; Pignatti P; Magri F; Chiovato L
J Interferon Cytokine Res; 2013 Sep; 33(9):508-13. PubMed ID: 23675779
[TBL] [Abstract][Full Text] [Related]
15. BRAFV600E and RET/PTC Promote Proliferation and Migration of Papillary Thyroid Carcinoma Cells In Vitro by Regulating Nuclear Factor-κB.
Zhou D; Li Z; Bai X
Med Sci Monit; 2017 Nov; 23():5321-5329. PubMed ID: 29117154
[TBL] [Abstract][Full Text] [Related]
16. Effects of phenformin on the proliferation of human tumor cell lines.
Caraci F; Chisari M; Frasca G; Chiechio S; Salomone S; Pinto A; Sortino MA; Bianchi A
Life Sci; 2003 Dec; 74(5):643-50. PubMed ID: 14623034
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells.
D'Agostino M; Voce P; Celano M; Sponziello M; Moretti S; Maggisano V; Verrienti A; Durante C; Filetti S; Puxeddu E; Russo D
Thyroid; 2012 Feb; 22(2):138-44. PubMed ID: 22191389
[TBL] [Abstract][Full Text] [Related]
18. The multifaceted anti-cancer effects of BRAF-inhibitors.
Croce L; Coperchini F; Magri F; Chiovato L; Rotondi M
Oncotarget; 2019 Nov; 10(61):6623-6640. PubMed ID: 31762942
[TBL] [Abstract][Full Text] [Related]
19. Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves' disease and ophthalmopathy.
Ferrari SM; Ragusa F; Paparo SR; Nasini F; Nardi M; Franceschini SS; Fallahi P; Antonelli A
Autoimmun Rev; 2019 Jul; 18(7):673-678. PubMed ID: 31059842
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma.
Petrachi T; Romagnani A; Albini A; Longo C; Argenziano G; Grisendi G; Dominici M; Ciarrocchi A; Dallaglio K
Oncotarget; 2017 Jan; 8(4):6914-6928. PubMed ID: 28036292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
